Acrivon Therapeutics Inc.... (ACRV)
NASDAQ: ACRV
· Real-Time Price · USD
1.31
-0.11 (-7.75%)
At close: May 06, 2025, 3:42 PM
-7.75% (1D)
| Bid | 1.31 |
| Market Cap | 41.23M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -80.56M |
| EPS (ttm) | -2.38 |
| PE Ratio (ttm) | -0.55 |
| Forward PE | -0.55 |
| Analyst | Buy |
| Ask | 1.32 |
| Volume | 408,718 |
| Avg. Volume (20D) | 516,856 |
| Open | 1.36 |
| Previous Close | 1.42 |
| Day's Range | 1.27 - 1.38 |
| 52-Week Range | 1.27 - 10.16 |
| Beta | 1.78 |
About ACRV
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics tha...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 15, 2022
Employees 75
Stock Exchange NASDAQ
Ticker Symbol ACRV
Website https://www.acrivon.com
Analyst Forecast
According to 6 analyst ratings, the average rating for ACRV stock is "Buy." The 12-month stock price forecast is $17, which is an increase of 1192.78% from the latest price.
Stock Forecasts1 week ago
-17.59%
ACRV stock has given up its prior gain. Acrivion T...
Unlock content with
Pro Subscription
1 week ago
-17.59%
Acrivion Therapeutics shares are trading higher after the company announced it will present data from its analysis of ACR-2316.
